Milestone exchanges 1.06M shares with RTW for pre-funded warrants; adds director Fischer

Milestone Pharmaceuticals Inc.

Exchanged 1,059,000 common shares with RTW Investments for pre-funded warrants at $0.001 exercise price, no expiration.
Warrants immediately exercisable; subject to 9.99% beneficial ownership limitation.
Seth H.Z. Fischer elected to Board, effective March 21, 2023; over 40 years pharma experience, including Johnson & Johnson.
Fischer receives $35,000 annual cash retainer and initial option for 42,000 shares vesting over 3 years.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Seth H.Z. Fischer

Director

MIST · Milestone Pharmaceuticals Inc.

Effective: 2023-03-21
Filed: March 27, 2023, 7:59 PM ET

voted to elect Seth H.Z. Fischer to the Board, effective as of March 21, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Seth H.Z. Fischer was elected as Director at Milestone Pharmaceuticals Inc..

Action: elected
Role: Director

Exact text from the filing

voted to elect Seth H.Z. Fischer to the Board, effective as of March 21, 2023

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Milestone Pharmaceuticals Inc. entered into Exchange Agreement with entities affiliated with RTW Investments valued at Exchanged 1,059,000 common shares for pre-funded warrants to purchase 1,059,000 common shares at $0. (effective 2023-03-22).

Action: entry
Agreement: equity purchase
Counterparty: entities affiliated with RTW Investments
Value: Exchanged 1,059,000 common shares for pre-funded warrants to purchase 1,059,000 common shares at $0.
Effective: 2023-03-22

Exact text from the filing

On March 22, 2023, Milestone Pharmaceuticals Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with entities affiliated with RTW Investments (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,059,000 shares of the Company’s common shares, no par value per share (the “Common Shares”), owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,059,000 Common Shares, with an exercise price of $0.001 per share and no expiration date.

View on SEC.gov

152 material agreements filed in the last 30 days. Browse all material agreements →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-037189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.